Search

Displaying results 1781 - 1790 of 8195 in total
  1. Drug

    Plerixafor

    go.drugbank.com/drugs/DB06809
    ApprovedInvestigational

    [A7118,L45678] As an inhibitor of CXCR4, plerixafor blocks the binding of its ligand, stromal cell-derived factor-1-alpha (SDF-1α). … Since CXCR4 and SDF-1α are involved in the trafficking and homing of CD34+ cells to the marrow compartment, blocking this interaction leads to an increase in CD34+ cell circulating levels.

  2. Drug

    Triheptanoin

    go.drugbank.com/drugs/DB11677
    ApprovedInvestigational

    Triheptanoin is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation.

  3. Drug

    TP-271

    go.drugbank.com/drugs/DB15040
    Investigational

    TP-271 is under investigation in clinical trial NCT02724085 (A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271).

  4. Drug

    PT-2385

    go.drugbank.com/drugs/DB16055
    Investigational

    PT-2385 is under investigation in clinical trial NCT03108066 (PT2385 for the Treatment of Von Hippel-lindau Disease-associated Clear Cell Renal Cell Carcinoma).

  5. Drug

    Mibefradil

    go.drugbank.com/drugs/DB01388
    ApprovedWithdrawn

    Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  6. Drug

    Dobutamine

    go.drugbank.com/drugs/DB00841
    ApprovedInvestigational

    A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery.

    Synonyms: DL-dobutamine, (±)-4-(2-((3-(p-hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol
  7. Drug

    Prasugrel

    go.drugbank.com/drugs/DB06209
    ApprovedInvestigational

    As a result, inhibition of ADP-mediated platelet activation and aggregation occurs.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates
  8. Drug

    Fesoterodine

    go.drugbank.com/drugs/DB06702
    Approved

    Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  9. Drug

    AS-8112

    go.drugbank.com/drugs/DB09207
    Experimental

    AS-8112 is a synthetic compound that acts as a selective antagonist at the dopamine receptor subtypes D2 and D3, and the serotonin receptor 5-HT3.

    Categories: Dopamine D2 Receptor Antagonists
  10. Drug

    Prussian blue

    go.drugbank.com/drugs/DB06783
    Approved

    It is insoluble in water but also tends to form a colloid thus can exist in either colloidal or water-soluble form, and an insoluble form. … It is orally administered for clinical purposes to be used as an antidote for certain kinds of heavy metal poisoning, such as thallium and radioactive isotopes of caesium.